{"id":"tdi01-suspension","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the angiotensin-converting enzyme (ACE), TDI01 suspension reduces the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation and decreased blood pressure. Additionally, the inhibition of ACE also reduces the breakdown of bradykinin, a vasodilatory peptide, further contributing to the antihypertensive effect.","oneSentence":"TDI01 suspension is a medication that targets the renin-angiotensin-aldosterone system (RAAS) to treat hypertension.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:39.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07464912","phase":"PHASE3","title":"A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)","status":"RECRUITING","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","startDate":"2025-12-24","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":508},{"nctId":"NCT06169722","phase":"PHASE1, PHASE2","title":"TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","startDate":"2024-02-06","conditions":"GVHD, Chronic","enrollment":60},{"nctId":"NCT06102083","phase":"PHASE2","title":"A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","startDate":"2023-11-02","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TDI01 suspension","genericName":"TDI01 suspension","companyName":"Beijing Tide Pharmaceutical Co., Ltd","companyId":"beijing-tide-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TDI01 suspension is a medication that targets the renin-angiotensin-aldosterone system (RAAS) to treat hypertension. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}